Yuan-Tzu Lan1, Shih-Ching Chang2, Shung-Haur Yang2, Chun-Chi Lin1, Huann-Sheng Wang2, Jeng-Kai Jiang2, Wei-Shone Chen2, Tzu-Chen Lin2, Shih-Hwa Chiou3, Jen-Kou Lin4. 1. Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan; Department of Surgery, National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan. 2. Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan; Department of Surgery, National Yang-Ming University, Taipei, Taiwan. 3. Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. 4. Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, 201 Section 2, Shih-Pai Road, Taipei 11217, Taiwan; Department of Surgery, National Yang-Ming University, Taipei, Taiwan. Electronic address: jklin@vghtpe.gov.tw.
Abstract
BACKGROUND: Despite curative surgery for colorectal cancer, some patients experience tumor recurrence. Whether early recurrence is associated with a shorter postrecurrence survival period compared with late recurrence remains unknown. METHODS: A total of 395 patients with tumor recurrence after curative surgery for colorectal cancer were enrolled and divided into early (<3 years) and late (≥3 years) recurrence groups. Clinicopathologic characteristics, recurrence patterns, and postrecurrence survival were compared. RESULTS: For stage I and II colorectal cancer, patients with T4 lesions tended to experience early recurrence. For stage III colorectal cancer, early recurrence was more common in patients with N2 disease. Patients with older age, mucinous-type tumors, poorly differentiated histology, the presence of lymphovascular invasion, or multiple site recurrence tended to die <2 years after recurrence. Median postrecurrence survival was similar for the 2 groups. Patients undergoing resection of liver or lung metastases demonstrated longer postrecurrence survival compared with those who did not undergo resection. CONCLUSIONS: Compared with late recurrence, early recurrence does not indicate a worse outcome in colorectal cancer.
BACKGROUND: Despite curative surgery for colorectal cancer, some patients experience tumor recurrence. Whether early recurrence is associated with a shorter postrecurrence survival period compared with late recurrence remains unknown. METHODS: A total of 395 patients with tumor recurrence after curative surgery for colorectal cancer were enrolled and divided into early (<3 years) and late (≥3 years) recurrence groups. Clinicopathologic characteristics, recurrence patterns, and postrecurrence survival were compared. RESULTS: For stage I and II colorectal cancer, patients with T4 lesions tended to experience early recurrence. For stage III colorectal cancer, early recurrence was more common in patients with N2 disease. Patients with older age, mucinous-type tumors, poorly differentiated histology, the presence of lymphovascular invasion, or multiple site recurrence tended to die <2 years after recurrence. Median postrecurrence survival was similar for the 2 groups. Patients undergoing resection of liver or lung metastases demonstrated longer postrecurrence survival compared with those who did not undergo resection. CONCLUSIONS: Compared with late recurrence, early recurrence does not indicate a worse outcome in colorectal cancer.
Authors: Mark A Healy; Jason C Pradarelli; Robert W Krell; Scott E Regenbogen; Pasithorn A Suwanabol Journal: Dis Colon Rectum Date: 2016-11 Impact factor: 4.585
Authors: Patrick Mayr; Georg Aumann; Tina Schaller; Gerhard Schenkirsch; Matthias Anthuber; Bruno Märkl Journal: Langenbecks Arch Surg Date: 2016-02-16 Impact factor: 3.445
Authors: Amanda N Lisby; John C Flickinger; Babar Bashir; Megan Weindorfer; Sanjna Shelukar; Madison Crutcher; Adam E Snook; Scott A Waldman Journal: Expert Rev Precis Med Drug Dev Date: 2021-02-02
Authors: Jolanta Żok; Michał Bieńkowski; Barbara Radecka; Jan Korniluk; Krzysztof Adamowicz; Renata Duchnowska Journal: BMC Cancer Date: 2021-05-10 Impact factor: 4.430